Favorable first-pass recanalization rates with NeVa™ thrombectomy device in acute stroke patients: Initial clinical experience.
Acute stroke
NeVa™ device
excellent outcome
first-pass recanalization
thrombectomy device
Journal
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
ISSN: 2385-2011
Titre abrégé: Interv Neuroradiol
Pays: United States
ID NLM: 9602695
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
pubmed:
4
7
2020
medline:
25
11
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
The NeVa™ thrombectomy device (Vesalio LLC, Nashville, USA) has been reported to succeed in large vessel occlusion thrombectomy in animal, in-vitro, and clinical studies. Designed with Drop Zone technology, a closed distal tip, and strong expansive radial force, the device demonstrated particular efficiency in resistant "white" thrombi in preclinical research. Our goal is to determine the safety and performance of this novel stent retriever on first-pass rates and overall recanalization. The Interventional Neurology Database is a prospectively maintained database of anterior and posterior circulation stroke thrombectomy cases. We retrospectively analyzed cases where the NeVa™ thrombectomy device was used as the first-line treatment strategy. Data collection occurred between January 2019 and January 2020. First-pass recanalization, final recanalization, 90-day functional outcome, complication, and bleeding rates are reported. One hundred eighteen patients were treated with the NeVa™ thrombectomy device. The mean patient age was 69 ± 14 years, the median baseline National Institutes of Health Stroke Scale was 14, and the median initial Alberta Stroke Program Early Computed Tomography score was 8. The median time from groin puncture to successful recanalization was 29 min (interquartile range (IQR): 20-40). First-pass recanalization rates were 56.8% (modified treatment in cerebral infarction (mTICI) 2b/3) and 44.9% (mTICI 2c/3). Final successful recanalization rate was 95.8% (thrombolysis in cerebral infarction 2b/3). Favorable functional outcome (modified Rankin Scale 0-2) was 53% in the "first-pass" subgroup and 42.4% in the total patient population. The median number of passes to achieve the final recanalization score was 1 (IQR 1-2). The rate of embolization into new territory was 1.7%. Four patients (3.3%) had symptomatic hemorrhage. In our experience, the NeVa™ device demonstrated high first-pass and overall recanalization rates along with a good safety profile.
Sections du résumé
BACKGROUND
BACKGROUND
The NeVa™ thrombectomy device (Vesalio LLC, Nashville, USA) has been reported to succeed in large vessel occlusion thrombectomy in animal, in-vitro, and clinical studies. Designed with Drop Zone technology, a closed distal tip, and strong expansive radial force, the device demonstrated particular efficiency in resistant "white" thrombi in preclinical research. Our goal is to determine the safety and performance of this novel stent retriever on first-pass rates and overall recanalization.
METHODS
METHODS
The Interventional Neurology Database is a prospectively maintained database of anterior and posterior circulation stroke thrombectomy cases. We retrospectively analyzed cases where the NeVa™ thrombectomy device was used as the first-line treatment strategy. Data collection occurred between January 2019 and January 2020. First-pass recanalization, final recanalization, 90-day functional outcome, complication, and bleeding rates are reported.
RESULTS
RESULTS
One hundred eighteen patients were treated with the NeVa™ thrombectomy device. The mean patient age was 69 ± 14 years, the median baseline National Institutes of Health Stroke Scale was 14, and the median initial Alberta Stroke Program Early Computed Tomography score was 8. The median time from groin puncture to successful recanalization was 29 min (interquartile range (IQR): 20-40). First-pass recanalization rates were 56.8% (modified treatment in cerebral infarction (mTICI) 2b/3) and 44.9% (mTICI 2c/3). Final successful recanalization rate was 95.8% (thrombolysis in cerebral infarction 2b/3). Favorable functional outcome (modified Rankin Scale 0-2) was 53% in the "first-pass" subgroup and 42.4% in the total patient population. The median number of passes to achieve the final recanalization score was 1 (IQR 1-2). The rate of embolization into new territory was 1.7%. Four patients (3.3%) had symptomatic hemorrhage.
CONCLUSIONS
CONCLUSIONS
In our experience, the NeVa™ device demonstrated high first-pass and overall recanalization rates along with a good safety profile.
Identifiants
pubmed: 32615827
doi: 10.1177/1591019920938223
pmc: PMC7903549
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-113Références
J Neurointerv Surg. 2014 Mar;6(2):83-6
pubmed: 23390038
Stroke. 2012 Jun;43(6):1657-9
pubmed: 22442176
Stroke. 2015 Oct;46(10):2838-42
pubmed: 26374483
Stroke. 2013 Oct;44(10):2802-7
pubmed: 23908066
J Neurointerv Surg. 2018 Aug;10(8):729-734
pubmed: 29246906
JAMA. 2017 Aug 1;318(5):443-452
pubmed: 28763550
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Cardiovasc Intervent Radiol. 2013 Feb;36(1):192-7
pubmed: 22699778
J Neurointerv Surg. 2016 Oct;8(10):992-5
pubmed: 26508129
J Neurointerv Surg. 2019 Nov;11(11):1095-1099
pubmed: 31048458
J Neurointerv Surg. 2019 Jul;11(7):625-629
pubmed: 30389897
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
Stroke. 2018 Mar;49(3):660-666
pubmed: 29459390
Stroke. 2018 May;49(5):1107-1115
pubmed: 29643261
J Neurointerv Surg. 2016 Oct;8(10):989-91
pubmed: 26888954
J Neurointerv Surg. 2017 Feb;9(2):117-121
pubmed: 26888952
JAMA Neurol. 2016 Mar;73(3):275-81
pubmed: 26810499
Interv Neuroradiol. 2017 Apr;23(2):166-172
pubmed: 28304200
Stroke. 2017 Sep;48(9):2488-2493
pubmed: 28775136
Stroke. 2020 Apr;51(4):1313-1316
pubmed: 32078495
J Neuroradiol. 2019 May;46(3):163-167
pubmed: 29625154
Clin Neuroradiol. 2016 Jun;26(2):221-8
pubmed: 25366714
Interv Neurol. 2018 Apr;7(5):205-217
pubmed: 29765390
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Stroke. 2018 Oct;49(10):2523-2525
pubmed: 30355115
Neuroradiology. 2014 May;56(5):397-403
pubmed: 24619135
AJNR Am J Neuroradiol. 2011 Feb;32(2):294-300
pubmed: 20966052
J Neuroradiol. 2021 Feb;48(1):5-9
pubmed: 31539584
AJNR Am J Neuroradiol. 2016 Jan;37(1):114-9
pubmed: 26294644
Lancet. 2019 Mar 9;393(10175):998-1008
pubmed: 30860055
J Neurointerv Surg. 2019 Mar;11(3):296-299
pubmed: 30262657
J Neurointerv Surg. 2017 Mar;9(3):257-263
pubmed: 27016318
AJNR Am J Neuroradiol. 2012 Apr;33(4):643-8
pubmed: 22207297
J Neuroradiol. 2020 Jun;47(4):301-305
pubmed: 30951765
J Neurointerv Surg. 2018 Jun;10(6):525-529
pubmed: 28963362
J Neurointerv Surg. 2018 Jul;10(Suppl 1):i4-i7
pubmed: 30037944
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396